Inicio・Lista de Acciones・Novavax Inc

Novavax Inc

Cerrado

SectorSanidad

7.65 3.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.4

Máximo

7.6899999999999995

Métricas clave
By Trading Economics
Ingresos	-27M -9.5M
Ventas	-7.6M 140M
P/B Media del Sector	3.112 64.641
BPA	-0.06
Margen de beneficios	-6.803
Empleados	749
EBITDA	-29M -543K

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+45.07% upside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-89M 1.2B
Apertura anterior	4.55
Cierre anterior	7.65

Noticias sobre sentimiento de mercado

By Acuity

50%

151 / 340 Clasificación en Healthcare

Novavax Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 jul 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 jul 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 jul 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 jul 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 jul 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 jul 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 jul 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 jul 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 jul 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 jul 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Novavax Inc previsión

Precio Objetivo

By TipRanks

45.07% repunte

Estimación a 12 Meses

Media 10.75 USD 45.07%

Máximo 19 USD

Mínimo 7 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novavax Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Novavax Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

151 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.